https://www.selleckchem.com/sc....reening/fda-approved
6-100%) and specificity of 100% (95% CI 89.6-100%) were observed for this pilot series. We demonstrate that gw-NIPS is a potential option for a majority of reciprocal translocation carriers. Further confirmation of this methodology could lead to adoption of this noninvasive alternative. We demonstrate that gw-NIPS is a potential option for a majority of reciprocal translocation carriers. Further confirmation of this methodology could lead to adoption of this noninvasive alternative. Galactokinase (GALK1) deficiency is
Curtir
Comentario
Compartilhar
